Cytosorbents (CTSO) Capital Expenditures Growth (5y) (2016 - 2026)
Powered by 
Analysis
Cytosorbents (CTSO) Capital Expenditures Growth (5y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -55.35% |
| Mar 31, 2026 | -51.93% |
| Dec 31, 2025 | -7.79% |
| Sep 30, 2025 | -40.60% |
| Jun 30, 2025 | -35.95% |
| Mar 31, 2025 | 1.44% |
| Dec 31, 2024 | -13.29% |
| Sep 30, 2024 | 3.76% |
| Jun 30, 2024 | -33.66% |
| Mar 31, 2024 | -31.17% |
| Dec 31, 2023 | -11.55% |
| Sep 30, 2023 | 39.45% |
| Jun 30, 2023 | -23.97% |
| Mar 31, 2023 | 15.97% |
| Dec 31, 2022 | -12.27% |
| Sep 30, 2022 | 12.80% |
| Jun 30, 2022 | 81.20% |
| Mar 31, 2022 | 97.55% |
| Dec 31, 2021 | 153.34% |
| Sep 30, 2021 | 73.10% |